| Q36990620 | 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation |
| Q27666463 | A dimeric structure of PD-L1: functional units or evolutionary relics? |
| Q55336684 | A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. |
| Q48256829 | A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. |
| Q28087576 | A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy |
| Q36170597 | Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell |
| Q33515211 | Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells |
| Q47607418 | Activation-induced polarized recycling targets T cell antigen receptors to the immunological synapse; involvement of SNARE complexes. |
| Q61714884 | Altered phenotype and function of dendritic cells in children with type 1 diabetes |
| Q28610420 | An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells |
| Q35973425 | An innately interesting decade of research in immunology |
| Q91655699 | Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses |
| Q28082259 | Anti-programmed cell death protein-1/ligand-1 therapy in different cancers |
| Q35637379 | Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases |
| Q34726206 | Assembly of the immunological synapse for T cells and NK cells |
| Q36935749 | At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy |
| Q46346021 | B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse |
| Q34959906 | Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients |
| Q39190801 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma |
| Q35733829 | Biology of T lymphocytes |
| Q36480617 | Biomarkers on melanoma patient T cells associated with ipilimumab treatment |
| Q24292957 | Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production |
| Q33455698 | CD152 (CTLA-4) determines CD4 T cell migration in vitro and in vivo |
| Q38343937 | CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. |
| Q28244243 | CD28 and CTLA-4 coreceptor expression and signal transduction |
| Q27007031 | CD28 co-stimulation in T-cell homeostasis: a recent perspective |
| Q30478206 | CD80 cytoplasmic domain controls localization of CD28, CTLA-4, and protein kinase Ctheta in the immunological synapse |
| Q56888824 | CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism |
| Q26777563 | CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition |
| Q35624717 | CTLA-4 and tolerance: the biochemical point of view |
| Q40569367 | CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems |
| Q24622666 | CTLA-4 blockade: therapeutic potential in cancer treatments |
| Q56902383 | CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production in T-cell hybridomas |
| Q48239167 | CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation. |
| Q28279561 | CTLA-4 trafficking and surface expression |
| Q50125551 | CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation |
| Q34711491 | CTLA-4: new insights into its biological function and use in tumor immunotherapy |
| Q33808334 | CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells |
| Q40266751 | CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells |
| Q36079873 | CTLA4 gene polymorphism and autoimmunity |
| Q56891117 | Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity |
| Q38106230 | Cancer immunotherapies, their safety and toxicity. |
| Q33731047 | Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets |
| Q26766419 | Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition |
| Q35223235 | Cell surface signaling molecules in the control of immune responses: a tide model. |
| Q90479767 | Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy |
| Q56889794 | Characterization of CTLA4 Trafficking and Implications for Its Function |
| Q26745442 | Checkpoint Inhibitors and Their Application in Breast Cancer |
| Q36490768 | Checkpoint blockade in cancer immunotherapy |
| Q38611369 | Checkpoint blockade in combination with cancer vaccines |
| Q33651495 | Checkpoint inhibitors in hematological malignancies |
| Q40712115 | Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells |
| Q35762422 | Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity |
| Q38804454 | Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future? |
| Q28271806 | Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily |
| Q34658652 | Comparison of the intracellular trafficking itinerary of ctla-4 orthologues |
| Q38070788 | Compartmentalization of signaling by vesicular trafficking: a shared building design for the immune synapse and the primary cilium |
| Q35020830 | Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection |
| Q38315713 | Confusing signals: recent progress in CTLA-4 biology |
| Q35842036 | Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation |
| Q46556005 | Continuous T cell receptor signaling required for synapse maintenance and full effector potential |
| Q36717167 | Control of T cell antigen reactivity via programmed TCR downregulation. |
| Q35856744 | Control of immune responses by trafficking cell surface proteins, vesicles and lipid rafts to and from the immunological synapse |
| Q36617078 | Control of interleukin-2 gene transcription: a paradigm for inducible, tissue-specific gene expression |
| Q36402656 | Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen |
| Q34872786 | Costimulation couture: a designer approach to regulating autoimmunity |
| Q24296901 | Costimulation induced phosphorylation of L-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25 |
| Q27640589 | Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling |
| Q26773314 | Current status of immunotherapy |
| Q38779877 | Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy |
| Q34015965 | Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice |
| Q38577834 | Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade |
| Q35208771 | Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation |
| Q24336767 | Degradation of Bcl10 induced by T-cell activation negatively regulates NF-kappa B signaling |
| Q89944648 | Determinants of Resistance to Checkpoint Inhibitors |
| Q34098531 | Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling |
| Q30504688 | Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses |
| Q38299845 | Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4. |
| Q37812670 | Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters |
| Q35550692 | Dynamics of Cell Surface Molecules During T Cell Recognition |
| Q40683782 | Dynamics of p56lck translocation to the T cell immunological synapse following agonist and antagonist stimulation |
| Q28205720 | ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum |
| Q43262540 | Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry. |
| Q24796946 | Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells |
| Q56889222 | Endocrine toxicity of cancer immunotherapy targeting immune checkpoints |
| Q34189022 | Engagement of CD99 triggers the exocytic transport of ganglioside GM1 and the reorganization of actin cytoskeleton. |
| Q37114367 | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? |
| Q51000594 | Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia. |
| Q24299640 | Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells |
| Q46027912 | Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. |
| Q64883724 | Fire in the Smoke: Battling Brain Tumors. |
| Q34612487 | Formation and function of the immunological synapse |
| Q37406665 | From tango to quadrilla: current views of the immunological synapse. |
| Q64110950 | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| Q28086999 | Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors |
| Q51724569 | Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. |
| Q45411485 | Human immunodeficiency virus (HIV) type 1 Vpr induces differential regulation of T cell costimulatory molecules: direct effect of Vpr on T cell activation and immune function |
| Q92950320 | Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy |
| Q55114350 | Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. |
| Q38396568 | Immune checkpoint inhibition in lymphoid disease. |
| Q55024216 | Immune checkpoint inhibitors and radiotherapy-concept and review of current literature. |
| Q38988058 | Immune checkpoint inhibitors for cancer treatment. |
| Q47400647 | Immune checkpoint inhibitors: new strategies to checkmate cancer |
| Q95936576 | Immune checkpoint signaling and cancer immunotherapy |
| Q39363726 | Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. |
| Q38284898 | Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway |
| Q39262779 | Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses |
| Q38485334 | Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia |
| Q36717901 | Immunostimulatory monoclonal antibodies for cancer therapy |
| Q39026963 | Immunosuppression in liver tumors: opening the portal to effective immunotherapy. |
| Q41183693 | Immunotherapy earns its spot in the ranks of cancer therapy |
| Q38367414 | Immunotherapy for lung cancer: for whom the bell tolls? |
| Q40099075 | Immunotherapy of cancers comes of age. |
| Q27003955 | Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? |
| Q36020800 | Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients |
| Q34872848 | Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. |
| Q51807589 | Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. |
| Q35005865 | Interface accumulation of receptor/ligand couples in lymphocyte activation: methods, mechanisms, and significance |
| Q34646640 | Intracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma. |
| Q46424205 | Intracellular concentrations of Ca(2+) modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte antigen-4 (CD152)-CD80/CD86 interactions in CD4(+) T lymphocytes |
| Q37864700 | Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family |
| Q38069640 | Ipilimumab in prostate cancer |
| Q41921890 | Maintaining system homeostasis: the third law of Newtonian immunology |
| Q36629861 | Maintenance and modulation of T cell polarity |
| Q33838467 | Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. |
| Q37553914 | Mechanisms and functions for the duration of intercellular contacts made by lymphocytes |
| Q26738671 | Melanoma immunotherapy dominates the field |
| Q38056851 | Microspectroscopy reveals mechanisms of lymphocyte activation |
| Q36399410 | Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance |
| Q34344753 | Modeling and experimental analyses reveals signaling plasticity in a bi-modular assembly of CD40 receptor activated kinases |
| Q64072797 | Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy |
| Q35901490 | Multiple costimulatory modalities enhance CTL avidity |
| Q24793730 | Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases |
| Q50796572 | Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. |
| Q26796086 | Narrowing the Gap: Preserving Repertoire Diversity Despite Clonal Selection during the CD4 T Cell Response |
| Q92705028 | Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States |
| Q34612576 | Negative co-receptors on lymphocytes |
| Q35096700 | Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors |
| Q36370461 | Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. |
| Q37474904 | Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections |
| Q58804962 | New developments in immunotherapy for lymphoma |
| Q26781931 | New developments in the management of advanced melanoma - role of pembrolizumab |
| Q56900749 | Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody |
| Q52657150 | Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles. |
| Q48150082 | PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease. |
| Q42991820 | Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake |
| Q36593312 | Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications |
| Q40814414 | Polyphenol administration impairs T-cell proliferation by imprinting a distinct dendritic cell maturational profile |
| Q90737500 | Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors |
| Q36007588 | Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen-specific manner |
| Q36389992 | Principles and use of anti-CTLA4 antibody in human cancer immunotherapy |
| Q30480631 | Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability |
| Q38855531 | Rab8 binding to immune cell-specific adaptor LAX facilitates formation of trans-Golgi network-proximal CTLA-4 vesicles for surface expression. |
| Q28239359 | Recruitment of the actin-binding protein HIP-55 to the immunological synapse regulates T cell receptor signaling and endocytosis |
| Q39672265 | Recycling and LFA‐1‐dependent trafficking of ICAM‐1 to the immunological synapse |
| Q37717709 | Regulation of CD4 T-cell receptor diversity by vaccine adjuvants |
| Q35090028 | Regulation of antiviral CD8+ T cells by inhibitory natural killer cell receptors |
| Q38377860 | Regulation of neutrophil functions through inhibitory receptors: an emerging paradigm in health and disease |
| Q35092535 | Regulatory T cells in transplantation tolerance |
| Q37728843 | Regulatory T cells: immune suppression and beyond |
| Q37834024 | Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis |
| Q34792489 | Reprogramming the immune system |
| Q38809776 | Reversing T-cell Dysfunction and Exhaustion in Cancer |
| Q96811967 | Sequencing Therapies for Metastatic Renal Cell Carcinoma |
| Q37055402 | Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication |
| Q90146774 | Single-nucleotide Polymorphism of CTLA-4 (rs5742909) in Correlation with Schizophrenia Risk Factor |
| Q46257343 | Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens. |
| Q42706743 | Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma |
| Q30488141 | Spatiotemporal patterning during T cell activation is highly diverse |
| Q30496881 | Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation |
| Q34634220 | Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens |
| Q30525394 | Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects |
| Q35685599 | Surfactant protein A integrates activation signal strength to differentially modulate T cell proliferation |
| Q42234959 | Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles |
| Q92405303 | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
| Q53073013 | T Cell Receptor-Regulated TGF-β Type I Receptor Expression Determines T Cell Quiescence and Activation. |
| Q47373840 | T cell activation: in vivo veritas |
| Q30856414 | T cell receptor (TCR) clustering in the immunological synapse integrates TCR and costimulatory signaling in selected T cells |
| Q34831128 | T cell-dendritic cell immunological synapses contain TCR-dependent CD28-CD80 clusters that recruit protein kinase C theta |
| Q34858190 | T-cell activation: a multidimensional signaling network. |
| Q46522042 | T-cell-antigen recognition and the immunological synapse |
| Q34044406 | TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo |
| Q44583959 | TCR subunit specificity of CTLA-4-mediated signaling |
| Q34862200 | TCR triggering on the move: diversity of T-cell interactions with antigen-presenting cells |
| Q33722462 | TGF-beta and regulatory T cell in immunity and autoimmunity |
| Q38963420 | Targeting Immune Checkpoints in Hematologic Malignancies |
| Q93141020 | Targeting Treg cells in cancer immunotherapy |
| Q36079881 | The B7/CD28 costimulatory family in autoimmunity |
| Q38751265 | The Immune Synapse: Past, Present, and Future |
| Q50119256 | The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis |
| Q38983022 | The T cell IFT20 interactome reveals new players in immune synapse assembly |
| Q38151850 | The actin-driven spatiotemporal organization of T-cell signaling at the system scale |
| Q27860852 | The blockade of immune checkpoints in cancer immunotherapy |
| Q44393406 | The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses |
| Q48173100 | The emerging role of immune checkpoint based approaches in AML and MDS. |
| Q37108443 | The great balancing act: regulation and fate of antiviral T-cell interactions |
| Q57961866 | The immunological synapse |
| Q36290302 | The many sounds of T lymphocyte silence. |
| Q36877341 | The molecular makeup and function of regulatory and effector synapses |
| Q48540784 | The reverse stop-signal model for CTLA4 function |
| Q35928357 | The role of coinhibitory signaling pathways in transplantation and tolerance |
| Q60044595 | The suppressive effect of co-inhibiting and expression on H22 hepatomas in mice |
| Q58924840 | The swinging pendulum of cancer immunotherapy personalization |
| Q56895374 | Therapeutic antibodies in cancer therapy |
| Q55268648 | Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. |
| Q39019379 | Trogocytosis of CD80 and CD86 by induced regulatory T cells |
| Q38730989 | Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors |
| Q35673845 | Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition |
| Q34650772 | Tuning immune responses: diversity and adaptation of the immunological synapse. |
| Q27310781 | Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues |
| Q28189055 | Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling |
| Q33734281 | Vaccines against human carcinomas: strategies to improve antitumor immune responses |
| Q90133819 | Versatile and High-throughput Force Measurement Platform for Dorsal Cell Mechanics |
| Q35177419 | Viewpoint: therapeutic implications of CTLA-4 compartmentalization |
| Q40751166 | Visualization of Cell-Cell Interaction Contacts: Synapses and Kinapses |
| Q35680821 | Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function |
| Q35155949 | What's the difference between CD80 and CD86? |